-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On June 11, Japan’s Daiichi Sankyo Co.
Upgraded version of G207
The past and present of G47∆
HSV-1 G207 was developed by the team of Dr.
Dr.
Stones from other mountains are enough for jade
T-VEC's original research team lays a solid foundation for research and development
As early as 2003, the British BioVex research team published an article in "Gene Therapy", proving that the deletion of ICP47 by HSV1 significantly enhanced the anti-tumor effect in BALB/c mice [3]
Hundreds of birds compete for the stream, and those who strive first
The clinical data of two oncolytic herpes simplex viruses under study is stunning
The currently approved T-VEC and G47Δ both use herpes simplex virus as a carrier, and knock out ICP34.
Replimune RP1
Robert Coffin, co-founder and CEO of American Replimune, was previously the founder of British BioVex, and T-VEC is the product of Amgen’s acquisition of BioVex
In April 2021, an article published in the Journal for ImmunoTherapy of Cancer published the clinical trial results of the safety, tolerability and anti-tumor activity of Binhui Bio-OH2 injection applied to patients with advanced solid tumors [5]
Herpes simplex virus also has the characteristics of large genome capacity, immunomodulatory molecules (such as: hGM-CSF, IL-2, IL-4, IL-10, IL-12, etc.
Reference
Reference[1] Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing.
[1] Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing.
[2] Relying on the IIT data from the phase II single-arm trial, Daiichi Sankyo applied for oncolytic virus drugs to be marketed in Japan |
[3] ICP34.
[3] ICP34.
[4] Replimune Poster Presentation of RP1 Update in the Skin Cancer Cohorts at the Society for Immunotherapy of Cancer (SITC) 2020Annual Meeting
[5] Intratumoral OH2, an oncolytic herpes simplex virus 2, in patients with advanced solid tumors: a multi-center, phase 1/2 clinical trial.
J Immunother Cancer.
2021 Apr;9(4):e002224.
doi: 10.
1136/ jitc-2020-002224.
J Immunother Cancer.
2021 Apr;9(4):e002224.
doi: 10.
1136/ jitc-2020-002224.
